ADMA Biologics, Inc.
NASDAQ:ADMA
17.4 (USD) • At close December 20, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 258.215 | 154.08 | 80.943 | 42.22 | 29.349 | 16.985 | 22.761 | 10.661 | 7.178 | 5.916 | 3.068 | 1.118 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue
| 169.273 | 118.815 | 79.769 | 61.291 | 39.504 | 42.195 | 29.164 | 6.361 | 4.311 | 3.742 | 2.023 | 0.669 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit
| 88.942 | 35.265 | 1.173 | -19.072 | -10.155 | -25.209 | -6.404 | 4.3 | 2.866 | 2.173 | 1.044 | 0.449 | 0 | 0 | 0 | 0 | 0 |
| Gross Profit Ratio
| 0.344 | 0.229 | 0.014 | -0.452 | -0.346 | -1.484 | -0.281 | 0.403 | 0.399 | 0.367 | 0.34 | 0.402 | 0 | 0 | 0 | 0 | 0 |
| Reseach & Development Expenses
| 3.3 | 3.614 | 3.646 | 5.907 | 2.344 | 3.926 | 6.23 | 7.688 | 7.016 | 9.517 | 9.303 | 3.469 | 0 | 0 | 0 | 0 | 0 |
| General & Administrative Expenses
| 0 | 0 | 0 | 0 | 0 | 22.503 | 18.093 | 8.495 | 6.746 | 4.824 | 4.365 | 3.142 | 0.026 | 0.021 | 0 | 0 | 0.024 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 59.02 | 52.458 | 42.897 | 35.051 | 25.911 | 22.503 | 18.093 | 8.495 | 6.746 | 4.824 | 4.365 | 3.142 | 0.026 | 0.021 | 0 | 0 | 0.024 |
| Other Expenses
| 4.99 | 18.558 | 13.004 | 4.885 | 3.015 | -0.127 | -0.01 | 0.004 | 4.618 | -0.074 | 0.082 | 1.747 | 0.005 | 0.003 | -20.009 | 24.916 | 29.735 |
| Operating Expenses
| 66.586 | 74.63 | 59.547 | 45.843 | 31.269 | 35.08 | 32.061 | 21.631 | 18.38 | 18.192 | 16.087 | 8.358 | 0.026 | 0.021 | -20.009 | 24.916 | 29.735 |
| Operating Income
| 21.632 | -39.365 | -58.374 | -64.915 | -41.424 | -60.289 | -39.31 | -17.33 | -15.514 | -16.019 | -15.042 | -7.909 | -0.026 | -0.021 | -20.009 | -24.891 | -29.687 |
| Operating Income Ratio
| 0.084 | -0.255 | -0.721 | -1.538 | -1.411 | -3.549 | -1.727 | -1.626 | -2.161 | -2.708 | -4.904 | -7.074 | 0 | 0 | 0 | 0 | 0 |
| Total Other Income Expenses Net
| -49.871 | -26.75 | -13.513 | -10.834 | -6.855 | -5.455 | -4.449 | -2.185 | -2.456 | -1.346 | -0.485 | -0.01 | -6.198 | -5.927 | 0 | 0 | 0 |
| Income Before Tax
| -28.239 | -65.904 | -71.648 | -75.749 | -48.279 | -65.743 | -43.759 | -19.515 | -17.97 | -17.365 | -15.527 | -7.919 | -0.026 | -0.021 | -20.009 | -24.891 | -29.687 |
| Income Before Tax Ratio
| -0.109 | -0.428 | -0.885 | -1.794 | -1.645 | -3.871 | -1.923 | -1.831 | -2.504 | -2.935 | -5.062 | -7.082 | 0 | 0 | 0 | 0 | 0 |
| Income Tax Expense
| 0 | 19.279 | 12.805 | 11.857 | 8.766 | 5.455 | 4.449 | 2.185 | 2.456 | -0.552 | 0.485 | -0.618 | -0 | -0 | 0 | 0 | 0 |
| Net Income
| -28.239 | -85.183 | -84.453 | -87.605 | -57.045 | -65.743 | -43.759 | -19.515 | -17.97 | -16.813 | -15.527 | -7.301 | -0.026 | -0.021 | -20.009 | -24.891 | -29.687 |
| Net Income Ratio
| -0.109 | -0.553 | -1.043 | -2.075 | -1.944 | -3.871 | -1.923 | -1.831 | -2.504 | -2.842 | -5.062 | -6.53 | 0 | 0 | 0 | 0 | 0 |
| EPS
| -0.13 | -0.43 | -0.61 | -1.02 | -1.05 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 | -1.39 | -0.011 | -0.008 | -8 | -9.96 | -11.87 |
| EPS Diluted
| -0.13 | -0.43 | -0.61 | -1.02 | -1.05 | -1.45 | -1.91 | -1.61 | -1.73 | -1.81 | -2.38 | -1.39 | -0.011 | -0.008 | -8 | -9.96 | -11.87 |
| EBITDA
| 5.12 | -39.723 | -53.335 | -59.821 | -36.028 | -56.774 | -39.31 | -16.806 | -15.657 | -15.831 | -14.698 | -7.706 | -4.402 | -5.022 | -20.009 | -24.891 | -29.687 |
| EBITDA Ratio
| 0.02 | -0.255 | -0.715 | -1.517 | -1.363 | -3.343 | -1.634 | -1.576 | -2.091 | -2.718 | -4.806 | -6.892 | 0 | 0 | 0 | 0 | 0 |